Monoclonal antibodies in cancer therapy: Mechanisms, targets, and clinical applications.

Joel Fortin*

Department of oncogenetics, Paul Brousse University Hospital, France

Introduction

Monoclonal antibodies (mAbs) have emerged as a cornerstone of cancer therapy, revolutionizing the treatment landscape for various malignancies. These laboratory-engineered antibodies are designed to target specific antigens on cancer cells, enhancing the body's immune response against tumors. This article explores the mechanisms of action, primary targets, and clinical applications of monoclonal antibodies in oncology [1].

Monoclonal antibodies exert their therapeutic effects through several mechanisms. Primarily, they can bind to specific antigens on the surface of cancer cells, leading to direct inhibition of tumor growth. Additionally, mAbs can recruit immune effector cells to eliminate tumor cells via antibody-dependent cellular cytotoxicity (ADCC) or complement-dependent cytotoxicity (CDC) [2].

Furthermore, some monoclonal antibodies block essential signaling pathways, preventing cancer cell proliferation and survival.Monoclonal antibodies can be classified based on their origin and structure. Chimeric mAbs are partially human and partially murine, while humanized mAbs are primarily human with small murine components [3].

Fully human mAbs, derived from human sources, minimize immunogenicity and enhance safety profiles. Each type has specific advantages and limitations, influencing their clinical use.A range of antigens has been identified as targets for monoclonal antibody therapy. One of the most notable targets is the human epidermal growth factor receptor 2 (HER2), overexpressed in some breast cancers [4].

Trastuzumab (Herceptin) is a well-known mAb that targets HER2, significantly improving outcomes in patients with HER2-positive breast cancer. Other targets include CD20 in non-Hodgkin lymphoma and PD-1/PD-L1 in various solid tumors [5].

Monoclonal antibodies have shown remarkable efficacy in hematologic malignancies. Rituximab, targeting CD20, has transformed the treatment of B-cell non-Hodgkin lymphoma and chronic lymphocytic leukemia. Its use in combination with chemotherapy has resulted in improved response rates and overall survival. Additionally, anti-CD52 mAb alemtuzumab has been effective in treating chronic lymphocytic leukemia, demonstrating the potential of mAbs in blood cancers [6].

In solid tumors, the clinical application of monoclonal antibodies has also expanded. Trastuzumab remains a standard of care for HER2-positive breast cancer, while cetuximab, targeting the epidermal growth factor receptor (EGFR), is utilized in colorectal cancer and head and neck cancers. The combination of monoclonal antibodies with other therapeutic modalities, such as chemotherapy and targeted therapies, is becoming increasingly common to enhance treatment efficacy [7].

Monoclonal antibodies have played a pivotal role in the development of immune checkpoint inhibitors. Antibodies targeting PD-1 (e.g., pembrolizumab) and CTLA-4 (e.g., ipilimumab) have revolutionized the treatment of melanoma, lung cancer, and other malignancies. By blocking these inhibitory pathways, these mAbs enable the immune system to recognize and attack cancer cells more effectively, leading to durable responses in a subset of patients [8].

The future of monoclonal antibody therapy lies in combination strategies. Combining mAbs with other treatment modalities, such as chemotherapy, radiation, and other targeted therapies, has shown promise in overcoming resistance and improving outcomes. Ongoing clinical trials are investigating various combinations to optimize treatment regimens and maximize patient benefit [9].

While monoclonal antibodies are generally well-tolerated, they are not without side effects. Common adverse events include infusion reactions, allergic responses, and immunological side effects related to immune modulation. Understanding the safety profile of each mAb is essential for effective patient management, and ongoing monitoring for long-term effects is critical [10].

Conclusion

Monoclonal antibodies represent a significant advancement in cancer therapy, offering targeted and effective treatment options for various malignancies. Their diverse mechanisms of action, coupled with ongoing research into new targets and combination therapies, continue to enhance their role in oncology. As the understanding of cancer biology evolves, the potential for monoclonal antibodies to improve patient outcomes will only grow, reinforcing their importance in the fight against cancer.

***Correspondence to:** Joel Fortin, Department of oncogenetics, Paul Brousse University Hospital, France. E-mail: joel.fortin@aphp.fr

***Received:** 2-Nov-2024, Manuscript No. JMOT-24-151249; **Editor assigned:** 4-Nov-2024, PreQC No. JMOT-24-151249 (PQ); **Reviewed:** 18-Nov-2024, QC No. JMOT-24-151249; **Revised:** 25-Nov-2024, Manuscript No. JMOT-24-151249 (R); **Published:** 30-Nov-2024, DOI: 10.35841/jmot-9.6.240*

***Citation:** Fortin J. Monoclonal antibodies in cancer therapy: Mechanisms, targets, and clinical applications. J Med Oncl Ther. 2024;9(6):240.*

References

1. Zahavi D, Weiner L. Monoclonal antibodies in cancer therapy. Antibodies. 2020;9(3):34.
2. Glassman PM, Balthasar JP. Mechanistic considerations for the use of monoclonal antibodies for cancer therapy. Cancer Biol Med. 2014;11(1):20.
3. Castelli MS, McGonigle P, Hornby PJ. The pharmacology and therapeutic applications of monoclonal antibodies. Pharmacol Res Perspect. 2019;7(6):e00535.
4. Strome SE, Sausville EA, Mann D. A mechanistic perspective of monoclonal antibodies in cancer therapy beyond target-related effects. The oncologist. 2007;12(9):1084-95.
5. Modjtahedi H, Ali S, Essapen S. Therapeutic application of monoclonal antibodies in cancer: Advances and challenges. Br Med Bull. 2012;104(1):41-59.
6. Scott AM, Allison JP, Wolchok JD. Monoclonal antibodies in cancer therapy. Cancer Immun. 2012;12(1).
7. Redman JM, Hill EM, AlDeghaither D, et al. Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015;67(2):28-45.
8. Dienstmann R, Markman B, Tabernero J. Application of monoclonal antibodies as cancer therapy in solid tumors. Curr Clin Pharmacol. 2012;7(2):137-45.
9. Adams GP, Weiner LM. Monoclonal antibody therapy of cancer. Nat Biotechnol. 2005;23(9):1147-57.
10. Manso T, Kushwaha A, Abdollahi N, et al. Mechanisms of action of monoclonal antibodies in oncology integrated in IMGT/mAb-DB. Front Immunol. 2023;14:1129323.

Citation: *Fortin J. Monoclonal antibodies in cancer therapy: Mechanisms, targets, and clinical applications. J Med Oncl Ther. 2024;9(6):240.*